In this observational bi-center study we aim to provide a comprehensive investigation and comparison of pretreatment and longitudinal CRP levels as potential predictive biomarkers of treatment response, disease progression and death in patients with advanced NSCLC undergoing anti PD-1 or anti PD-L1 treatment. The gene discussed is CD274; the disease is non-small cell lung carcinoma.